title: Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
abstract: Cancer vaccines designed to elicit an antibody response that target antigenic sites on a tumor antigen must closely mimic the three-dimensional structure of the corresponding region on the antigen. We have designed a complex immunogen derived from the extracellular domain of human HER-2/neu-(626-649) that represents a three-dimensional epitope. We have successfully introduced two disulfide bonds into this sequence, thereby recapitulating the natural disulfide pairings observed in the native protein. To evaluate the immunogenicity of the doubly cyclized disulfide-linked peptide versus the free uncyclized peptide we examined the induction of antibody responses in both inbred and outbred mice strains, with both constructs eliciting high titered antibodies. The disulfide-paired specific antibodies exhibited enhanced cross-reactivity to HER-2/neu expressed on BT-474 cell line as determined by flow cytometry. The antitumor activities of the disulfidepaired specific antibodies did not improve the in vitro growth inhibition of human breast cancer cells overexpressing HER-2, but showed superior antitumor responses in the context of ADCC and interferon-gamma induction. Inbred mice (FVB/n) vaccinated with the disulfide-paired epitope exhibited a statistically significant reduction in the development of exogenously administered tumors in vivo compared with mice receiving either the free uncyclized or the promiscuous T-cell epitope (MVF) control peptide (p = 0.001). This study demonstrates the feasibility and importance of designing conformational epitopes that mimic the tertiary structure of the native protein for eliciting biologically relevant anti-tumor antibodies. Such approaches are a prerequisite to the design of effective peptide vaccines.
authors.affiliation: Departments of Obstetrics and Gynecology, Integrated Biomedical Sciences Graduate Program, Ohio State Biochemistry Program, Columbus, Ohio 43210, USA.
authors.forename: Naveen K
authors.initials: NK
authors.lastname: Dakappagari
authors.forename: Kenneth D
authors.initials: KD
authors.lastname: Lute
authors.forename: Sharad
authors.initials: S
authors.lastname: Rawale
authors.forename: Joan T
authors.initials: JT
authors.lastname: Steele
authors.forename: Stephanie D
authors.initials: SD
authors.lastname: Allen
authors.forename: Gary
authors.initials: G
authors.lastname: Phillips
authors.forename: R Todd
authors.initials: RT
authors.lastname: Reilly
authors.forename: Pravin T P
authors.initials: PT
authors.lastname: Kaumaya
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology; D001943:Breast Neoplasms / Q000276:immunology* / Q000628:therapy; D019496:Cancer Vaccines / Q000737:chemistry / Q000276:immunology; D004220:Disulfides; D018985:Epitopes, B-Lymphocyte / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D051379:Mice; D008813:Mice, Inbred ICR; D008969:Molecular Sequence Data; D009374:Neoplasms, Experimental / Q000276:immunology / Q000517:prevention & control; D010446:Peptide Fragments / Q000737:chemistry / Q000276:immunology; D011487:Protein Conformation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000737:chemistry / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000737:chemistry / Q000276:immunology
chemical_list: D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines; D004220:Disulfides; D018985:Epitopes, B-Lymphocyte; D007371:Interferon-gamma; D010446:Peptide Fragments; D018719:Erb-b2 Receptor Tyrosine Kinases; D014614:Vaccines, Synthetic